Feb 25, 2020 / 03:30PM GMT
Geoffrey Craig Porges - SVB Leerink LLC, Research Division - Director of Therapeutics Research, MD & Senior Biotechnology Analyst
Okay. We're going to get started in a few minutes -- in a few seconds, let me modify that, with our next company. Terrific. All right. Ready to get underway. So welcome to this session. I'm Geoff Porges, Director of Therapeutics Research. I'm delighted to welcome AbbVie to our conference today. AbbVie is represented by Mike Severino who's President, and I believe still Head of R&D as well; and Rob Michael, who's Executive Vice President and Chief Financial Officer. Gentlemen, thank you for joining us at our Global Healthcare Conference.
Questions and Answers:
Geoffrey Craig Porges - SVB Leerink LLC, Research Division - Director of Therapeutics Research, MD & Senior Biotechnology AnalystSo there's all sorts of things we could talk about, Mike, but maybe we could talk about the -- first of all, the new indication pipeline for your recently introduced medicines and some that are late stages. But could you talk about